Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl

Bibliography

• How many men get prostate cancer? 2014. Available from: http://www.cancer.org/cancer/prostatecancer/overviewguide/prostate-cancer-overview-key-statistics [Last accessed 23 December 2014]
   Google Scholar
• Dason S, Allard CB, Tong J, Shayegan B. Defining a new testosterone threshold for medical castration: Results from a prospective cohort series. Can Urol Assoc J 2013;7(5-6):E263–7
   PubMed Web of Science ®Google Scholar
• Persad R. Leuprorelin acetate in prostate cancer: a European update. Int J Clin Pract 2002;56(5):389–96
   PubMed Web of Science ®Google Scholar
• Gommersall LM, Hayne D, Shergill IS, et al. Luteinising hormone releasing hormone analogues in the treatment of prostate cancer. Expert Opin Pharmacother 2002;3(12):1685–92
   PubMedGoogle Scholar
• Lupron depot® (leuprolide acetate for depot suspension) [prescribing information]. Available from: http://www.rxabbvie.com/pdf/lupronuro_pi.pdf [Last accessed 29 January 2015]
   Google Scholar
• Rick FG, Schally AV. Bench-to-bedside development of agonists and antagonists of luteinizing hormone-releasing hormone for treatment of advanced prostate cancer. Urol Oncol 2015;33(6):270–4
   PubMed Web of Science ®Google Scholar
• Eckstein N, Haas B. Clinical pharmacology and regulatory consequences of GnRH analogues in prostate cancer. Eur J Clin Pharmacol 2014;70(7):791–8
   PubMed Web of Science ®Google Scholar
• Raina R, Pahalajani G, Agarwal A, Zippe C. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study. Asian J Androl 2007;9(2):253–8
   PubMed Web of Science ®Google Scholar
• Novara G, Galfano A, Secco S, et al. Impact of surgical and medical castration on serum testosterone level in prostate cancer patients. Urol Int 2009;82(3):249–55
   PubMed Web of Science ®Google Scholar
• Oefelein MG, Feng A, Scolieri MJ, et al. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000;56(6):1021–4
   PubMed Web of Science ®Google Scholar
• Zherdev AV, Byzova NA, Izumrudov VA, Dzantiev BB. Rapid polyelectrolyte-based immunofiltration technique for testosterone detection in serum samples. Analyst 2003;128(10):1275–80
   PubMed Web of Science ®Google Scholar
• van der Sluis TM, Bui HN, Meuleman EJ, et al. Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry. J Urol 2012;187(5):1601–6
   PubMed Web of Science ®Google Scholar
• Perachino M, Cavalli V, Bravi F. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int 2010;105(5):648–51
   PubMed Web of Science ®Google Scholar
• Bertaglia V, Tucci M, Fiori C, et al. Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer. Clin Genitourin Cancer 2013;11(3):325–30 e1
   PubMed Web of Science ®Google Scholar
• Klotz L, O’Callaghan C, Ding K, et al. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 Trial of intermittent versus continuous ADT. J Clin Oncol 2015;33(10):1151–6
   PubMed Web of Science ®Google Scholar
• Morote J, Orsola A, Planas J, et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 2007;178(4 Pt 1):1290–5
   PubMed Web of Science ®Google Scholar
• Reis LO. Variations of serum testosterone levels in prostate cancer patients under LH-releasing hormone therapy: an open question. Endocr Relat Cancer 2012;19(3):R93–8
   PubMed Web of Science ®Google Scholar
• Schulman C, Alcaraz A, Berges R, et al. Expert opinion on 6-monthly luteinizing hormone-releasing hormone agonist treatment with the single-sphere depot system for prostate cancer. BJU Int 2007;100(Suppl 1):1–5
   PubMed Web of Science ®Google Scholar
• Williams G, Lindsay S, Bowsher WG. Randomised crossover trial to assess the tolerability of LHRH analogue administration. Prostate Cancer Prostatic Dis 2003;6(2):187–9
   PubMed Web of Science ®Google Scholar
• ELIGARD® (leuprolide acetate for injectable suspension) [prescribing information]. 2014. Available from: http://www.eligard.com/Docs/Pdf/TOLMAR%20Pharmaceuticals_Web_PI_05-07-14.pdf [Last accessed 29 January 2015]
   Google Scholar
• Berges R. Eligard®: pharmacokinetics, effect on testosterone and PSA levels and tolerability. Eur Urol Suppl 2005;4:20–5
   Web of Science ®Google Scholar
• DeYoung MB, MacConell L, Sarin V, et al. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther 2011;13(11):1145–54
   PubMed Web of Science ®Google Scholar
• Kim K, Pack DW. Microspheres for drug delivery. In: Lee A, Lee J, editors. BioMEMS and Biomedical Nanotechnology. Springer; New York: 2006
   Google Scholar
• Lu JM, Wang X, Marin-Muller C, et al. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn 2009;9(4):325–41
   PubMed Web of Science ®Google Scholar
• Muller FO, Terblanche J, Schall R, et al. Pharmacokinetics of triptorelin after intravenous bolus administration in healthy males and in males with renal or hepatic insufficiency. Br J Clin Pharmacol 1997;44(4):335–41
   PubMed Web of Science ®Google Scholar
• Pandya Y, Sisodiya D, Dashora K. ATRIGEL®, implants and controlled released drug delivery system. Int J Biopharmaceutics 2014;5(3):208–13
   Google Scholar
• Hatefi A, Amsden B. Biodegradable injectable in situ forming drug delivery systems. J Control Release 2002;80(1-3):9–28
   PubMed Web of Science ®Google Scholar
• Malik K, Singh I, Nagpal M, Arora S. Atrigel: a potential parenteral controlled drug delivery system. Der Pharmacia Sinica 2010;1:74–81
   Google Scholar
• Perez-Marrero R, Tyler RC. A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer. Expert Opin Pharmacother 2004;5(2):447–57
   PubMed Web of Science ®Google Scholar
• Lundstrom EA, Rencken RK, van Wyk JH, et al. Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study. Clin Drug Investig 2009;29(12):757–65
   PubMed Web of Science ®Google Scholar
• Spitz A, Young JM, Larsen L, et al. Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer. Prostate Cancer Prostatic Dis 2012;15(1):93–9
   PubMed Web of Science ®Google Scholar
• McLeod D, Zinner N, Tomera K, et al. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2001;58(5):756–61
   PubMed Web of Science ®Google Scholar
• Chu FM, Jayson M, Dineen MK, et al. A clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2002;168(3):1199–203
   PubMed Web of Science ®Google Scholar
• Crawford ED, Sartor O, Chu F, et al. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2006;175(2):533–6
   PubMed Web of Science ®Google Scholar
• Sartor O, Dineen MK, Perez-Marreno R, et al. An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer. Urology 2003;62(2):319–23
   PubMed Web of Science ®Google Scholar
• Leuprolide 2014. Available from: http://www.cancer.org/treatment/treatmentsandsideeffects/guidetocancerdrugs/leuprolide [Last accessed 29 January 2015]
   Google Scholar
• Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care 2009;15(6):e22–33
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23(8):1296–310
   PubMed Web of Science ®Google Scholar
• Love RC. Strategies for increasing treatment compliance: the role of long-acting antipsychotics. Am J Health Syst Pharm 2002;59(22 Suppl 8):S10–15
   PubMedGoogle Scholar
• Burnier M, Santschi V, Favrat B, Brunner HR. Monitoring compliance in resistant hypertension: an important step in patient management. J Hypertens Suppl 2003;21(2):S37–42
   PubMedGoogle Scholar
• Wex J, Sidhu M, Odeyemi I, et al. Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation. Clinicoecon Outcomes Res 2013;5:257–69
   PubMedGoogle Scholar
• Fowler JE, Flanagan M, Gleason DM, et al. Evaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer. Urology 2000;55(5):639–42
   PubMed Web of Science ®Google Scholar
• Lawrentschuk N, Fernandes K, Bell D, et al. Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence. J Urol 2011;185(3):848–54
   PubMed Web of Science ®Google Scholar
• Perez-Marreno R, Chu FM, Gleason D, et al. A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. Clin Ther 2002;24(11):1902–14
   PubMed Web of Science ®Google Scholar
• TRELSTAR® (triptorelin pamoate injection, powder, lyophilized, for suspension) [prescribing information]. Available from: http://pi.actavis.com/data_stream.asp?product_group=1684&p=pi&language=E [Last accessed 31 March 2014]
   Google Scholar
• Zoladex® (goserelin acetate implant) [prescribing information]. Available from: http://www1.astrazeneca-us.com/pi/zoladex3_6.pdf [Last accessed 31 March 2015]
   Google Scholar
• Firmagon® (degarelix for injection) [prescribing information]. Available from: http://www.firmagon.us/full_pi.pdf
   Google Scholar
• Dias Silva E, Ferreira U, Matheus W, et al. Goserelin versus leuprolide in the chemical castration of patients with prostate cancer. Int Urol Nephrol 2012;44(4):1039–44
   PubMed Web of Science ®Google Scholar
• Heyns CF, Simonin MP, Grosgurin P, et al. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU Int 2003;92(3):226–31
   PubMed Web of Science ®Google Scholar
• Lee SH, Lee HM, Kim SW, et al. Is high-dose leuprorelin acetate effective and safe in asian men with prostate cancer? An open-label, non-comparative, multi-center clinical trial. Yonsei Med J 2014;55(2):310–15
   PubMed Web of Science ®Google Scholar
• Sharifi R, Bruskewitz RC, Gittleman MC, et al. Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer. Clin Ther 1996;18(4):647–57
   PubMed Web of Science ®Google Scholar
• Sharifi R, Knoll LD, Smith J, Kramolowsky E. Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer. Urology 1998;51(2):271–6
   PubMed Web of Science ®Google Scholar
• Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008;102(11):1531–8
   PubMed Web of Science ®Google Scholar
• FDA approved drug products. Drugs@FDA. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm [Last accessed 31 March 2015]
   Google Scholar
• Kao CC, Chang YH, Wu T, et al. Open, multi-center, phase IV study to assess the efficacy and tolerability of triptorelin in Taiwanese patients with advanced prostate cancer. J Chin Med Assoc 2012;75(6):255–61
   PubMed Web of Science ®Google Scholar
• Sartor AO. A new hormonal treatment option. Available from: http://www.medscape.org/viewarticle/438957_4 [Last accessed 25 February 2015]
   Google Scholar
• Drug Details: ELIGARD®. Drugs@FDA. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails [Last accessed 25 February 2015]
   Google Scholar
• Approval Package for Lupron® Depot. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/020517orig1s025s030s032Review.pdf [Last accessed 25 February 2015]
   Google Scholar
• Sharifi R, Browneller R, Leuprolide Study G. Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer. J Urol 2002;168(3):1001–4
   PubMed Web of Science ®Google Scholar